Activist investor Shah Capital, which owns 6.7% of Novavax's stock, has claimed that the vaccine developer has been “historically mismanaged” as the firm tries to install new members onto the biotech's board.Shah Capital said that for more than a year it has tried to address “self-inflicted problems which have undermined the success and sustainability of the company,” according to an April 15 public letter.

拥有Novavax 6.7%股份的维权投资者Shah Capital声称，由于该公司试图在生物技术董事会中安装新成员，疫苗开发商“历史上管理不善”。根据4月15日的一封公开信，Shah Capital表示，一年多来，它一直试图解决“自我造成的问题，这些问题破坏了公司的成功和可持续性”。

The investor also claimed that Novavax’s board has been unresponsive to those efforts.The firm also argued that Novavax’s stock is “now trading at a near record low.” The biotech's shares are currently trading at $4.22 on Monday morning, above the $3.50 mark they sunk to in February, but far below the $200 plus realms the stock was floating in at the height of the pandemic.The investor has nominated Suresh Katta, founder and CEO of clinical analytics company Saama, and Venkat Peri, CEO of healthcare company Quantiva Health, as two new independent directors.

该投资者还声称，Novavax的董事会对这些努力没有反应。该公司还辩称，Novavax的股票“目前交易价格接近历史新低”。周一上午，该生物技术公司的股票目前交易价格为4.22美元，高于2月份跌至的3.50美元，但远低于疫情最严重时该股票浮动的200多美元。该投资者提名临床分析公司Saama的创始人兼首席执行官Suresh Katta和医疗保健公司Quantiva Health的首席执行官Venkat Peri担任两名新的独立董事。

“Together these two individuals have the pragmatic knowhow and technology experience to help the board address many of the key issues we have identified as value destroyers for Novavax,” the Shah letter reads. Those “value destroyers” include “colossal marketing failures, a non-existent partnership strategy, no clear understanding of technology, questionable regulatory management, and ongoing operating losses and inefficiencies.”RelatedAfter steep cost cuts, Novavax's fourth-quarter performance falls short of expectations“Together these have contributed to a market capitalization to 2024 expected sales ratio of only 1X, compared to the 10X valuation possessed by its peer Moderna,” the letter continues, referencing the mRNA giant that became a household name a few years ago due to its COVID-19 shot, dubbed Spikeva.

沙阿在信中写道：“这两个人拥有实用的专有技术和技术经验，可以帮助董事会解决我们确定为Novavax价值破坏者的许多关键问题。”。这些“价值破坏者”包括“巨大的营销失败，不存在的合作战略，对技术的不清楚理解，可疑的监管管理，以及持续的运营亏损和效率低下。”与此相关的是，在大幅削减成本后，Novavax的第四季度业绩低于预期“这些因素共同导致市值达到2024年的预期销售率仅为1倍，而其同行Moderna的估值是10倍”，信中继续提到了这家mRNA巨头，该巨头几年前因其新型冠状病毒（COVID-19）而家喻户晓，被称为Spikeva。